NASDAQ:ESRX - Express Scripts Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$92.33 -3.47 (-3.62 %)
(As of 01/17/2019 04:45 AM ET)
Previous Close$95.80
Today's Range$92.11 - $95.87
52-Week Range$66.93 - $101.73
Volume31.61 million shs
Average Volume6.64 million shs
Market Capitalization$52.06 billion
P/E Ratio13.00
Dividend YieldN/A
Beta0.88
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Current Ratio0.77
Quick Ratio0.65

Price-To-Earnings

Sales & Book Value

Annual Sales$100.06 billion
Price / Sales0.52
Cash Flow$10.4920 per share
Price / Cash Flow8.80
Book Value$32.00 per share
Price / Book2.89

Profitability

Net Income$4.52 billion
Net Margins4.83%
Return on Assets8.94%

Miscellaneous

Employees26,600
Market Cap$52.06 billion
OptionableOptionable

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts announced that its board has authorized a stock repurchase program on Wednesday, December 20th 2017, which allows the company to buyback 45,000,000 shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts Holding Co (NASDAQ:ESRX) released its quarterly earnings data on Wednesday, October, 31st. The company reported $2.43 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.42 by $0.01. The business had revenue of $25.56 billion for the quarter, compared to analyst estimates of $25.11 billion. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The business's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.51 earnings per share. View Express Scripts' Earnings History.

When is Express Scripts' next earnings date?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Express Scripts.

What price target have analysts set for ESRX?

14 analysts have issued twelve-month target prices for Express Scripts' shares. Their predictions range from $77.00 to $101.00. On average, they anticipate Express Scripts' share price to reach $91.2727 in the next year. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Express Scripts.

What is the consensus analysts' recommendation for Express Scripts?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 1 sell rating, 11 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.

Has Express Scripts been receiving favorable news coverage?

News headlines about ESRX stock have trended positive on Thursday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Express Scripts earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Express Scripts' key competitors?

Who are Express Scripts' key executives?

Express Scripts' management team includes the folowing people:
  • Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
  • Mr. James M. Havel, Exec. VP & CFO (Age 63)
  • Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
  • Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
  • Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)

How do I buy shares of Express Scripts?

Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of ESRX stock can currently be purchased for approximately $92.33.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $52.06 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.

What is Express Scripts' official website?

The official website for Express Scripts is http://www.express-scripts.com.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  823 (Vote Outperform)
Underperform Votes:  605 (Vote Underperform)
Total Votes:  1,428
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel